Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D6*10 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker

Fig. 2

CYP2D6*10 genotype frequency and enzyme activity in healthy subjects and HCC patients. a The frequency distribution of CYP2D6*10 genotypes in HCC patients and a normal population. **P < 0.01 vs heathy subjects. b Kaplan–Meier curve for overall survival (OS) of HCC patients with the CC and TT genotype, P log-rank = 0.365. c CYP2D6 activity of in peritumor liver tissues of HCC patients and normal liver tissues. **P < 0.01 vs heathy subjects. d CYP2D6 activity in subjects with the TT and CC genotype in healthy subjects and HCC patients. *P < 0.05, ***P < 0.001, TT group vs CC group. HCC, hepatocellular carcinoma; Healthy means healthy subjects. Data were expressed as mean ± SEM, P value was calculated by Mann–Whitney U test

Back to article page